Oncology Services For Cancer Treatment Articles & Analysis
29 news found
Biopharma PEG, a key provider of premium polyethylene glycol (PEG) derivatives, is thrilled to announce a substantial expansion of its large-scale Good Manufacturing Practice (GMP) production capabilities. This strategic move is aimed at addressing the rising global demand for Lipid Nanoparticles (LNPs), which are vital for nucleic acid drug delivery, especially in mRNA-based therapies and ...
Bayer presents first Phase 1 results from its most advanced clinical Immuno-Oncology program, aryl hydrocarbon receptor (AhR) inhibitor BAY2416964 New preclinical data on Bayer’s DGK zeta inhibitor being featured in oral presentation in New Drugs on the Horizon session New preclinical data on mutEGFR HER2 program, currently in Phase 1, will be presented Bayer ...
ByBayer AG
Stemline Therapeutics (“Stemline”), a wholly-owned subsidiary of the Menarini Group, headquartered in New York and focused on bringing transformational oncology treatments for cancer patients, will commercialize ORSERDU in the U.S. ...
PHILADELPHIA, Dec. 08, 2022 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a women’s oncology company developing novel treatments for breast and gynecologic cancers, announced preliminary Phase 2 data from the ongoing SMILE trial of onapristone extended release (ONA-XR), the company’s novel, first-in-class, potent, ...
” “We have brought a number of unique oncology treatments to patients over the past years,” said Christine Roth, Member of the Executive Committee of Bayer’s Pharmaceutical Division and Head of the Oncology SBU at Bayer. “Our ambition is to play a significant role in the next wave of breakthrough innovations in ...
ByBayer AG
Xilis, Inc., a pioneering company developing its MicroOrganoSphere™ (MOS) technology to guide precision therapy for cancer patients and accelerate drug discovery and development, announced today that it is participating in the recently announced public-private Oncode-PACT. Led by the Netherlands-based Oncode Institute, the consortium will be supported by the National Growth Fund, an ...
Xilis, Inc., a pioneering company developing its MicroOrganoSphere (MOS) technology to guide precision therapy for cancer patients and accelerate drug discovery and development, announced today that breast cancer oncologist Daniel F. Hayes, MD, FACP, FASCO, has joined the company’s Clinical Advisory Board (CAB). Dr. Hayes is a Professor of Internal Medicine, the Stuart B. Padnos Professor ...
Ascelia Pharma today announced and welcomed the results of independent market research showing that 84% of healthcare professionals will likely use Orviglance for magnetic resonance imaging (MRI) in patients with cancer in the liver and reduced kidney function. The independently conducted survey asked 270 healthcare professionals in the US (radiologists, oncologists and nephrologists) about ...
Ascelia Pharma AB (publ) (ticker: ACE) today announced that the last patient visit has been completed in the clinical study to evaluate the effect of liver impairment on the safety, pharmacokinetics and pharmacodynamics of the company’s lead drug candidate Orviglance. Preliminary results show that Orviglance was well tolerated in patients with liver impairment. The study is part of the ...
Joint research of biomarkers on platform technology of GI Innovation, GI-SMART™, and SpAC9 Pipeline, AI-powered biomarker discovery platform of CellKey Prediction of drug response on next-generation immuno-oncology, personalized cancer treatment effects… increasing reliability and efficiency of treatment GI Innovation, an innovative new drug development company, announced on ...
Joint research of biomarkers on platform technology of GI Innovation, GI-SMARTTM and SpAC9 Pipeline, AI-powered biomarker discovery platform of CellKey Prediction of drug response on next generation immuno-oncology, personalized cancer treatment effects… increasing Reliability and efficiency of treatment GI Innovation, a new innovative drug development company, announced on February ...
Milan, January 27, 2022 – InnovHeart s.r.l., a developer of novel Transcatheter Mitral Valve Replacement (TMVR) systems for the treatment of mitral valve disease, announces the closing of its Series C financing with granting an exclusive licensing agreement to Grand Pharmaceutical Group Limited, (Grand Pharma) for its proprietary Saturn device in Greater China. The transaction pulled in ...
CMR Surgical – the global surgical robotics business – has today announced the successful completion of high-volume urological procedures at the Sindh Institute of Urology and Transplantation (SIUT) using the next generation surgical robotic system, Versius®, in Pakistan. SIUT is a renowned, charitable institute, providing free state of the art medical treatment to all patients, ...
Technology is a first-of-its kind molecular pathway designed to suspend cancer, inhibit pain, and regenerate bone Study will examine the safety and efficacy of ZetaMetTM in the treatment of metastatic bone lesions as part of advanced stage cancer therapy Study is targeting Stage 4 breast cancer patients who have metastatic lesions in their spinal vertebrae Zetagen Therapeutics, a private, ...
“Although the number of oncology treatments has increased, there is more work to be done to ensure all patients are getting the best, most targeted therapies for their specific diseases. ...
The technology is a first-of-its kind molecular pathway designed to suspend cancer, inhibit pain, and regenerate bone Zetagen Therapeutics is developing the therapy for patients living with metastatic bone lesions and other osteologic conditions The Company is targeting its first human clinical trial for metastatic bone lesions to begin in early 2022 Zetagen Therapeutics, a private, ...
Kheiron Medical Technologies today announced its new collaboration with researchers at Stanford University to design functional proof-of-concept deep learning models to solve clinical problems in novel ways, starting with Non-Hodgkin’s Lymphoma (NHL). With the collaboration, Kheiron, which has pioneered the development and deployment of artificial intelligence solutions to help radiologists ...
SEATTLE, April 29, 2021 (GLOBE NEWSWIRE) -- SEngine Precision Medicine, a precision oncology company that pre-tests drugs on live tumor specimens employing its CLIA certified PARIS® Test, today announced that new data from a study summarizing the predictive value of the PARIS® Test across solid tumor cancers will be presented during a poster session (abstract number 2602) at the American ...
U.S.-based biopharmaceutical company has discovered and patented a novel molecular pathway intended to treat metastatic bone lesions Latest patent issuance follows previous patents for methods in stimulating bone growth, promote controlled bone creation and repair of large segmental bone defects using ZetaMet™ Company’s intellectual property pipeline targets other oncologic ...
Utrecht, The Netherlands & Philadelphia – LAVA Therapeutics, a biotech company pioneering the development of bispecific antibodies to engage gamma-delta T cells for cancer therapies, today announced the closing of an oversubscribed $83 million (€71 million) Series C financing to fund the advancement of its pipeline and platform. The financing was co-led by new investors Novo ...